Wendy Naimark
Chief Technology Officer Ripple Therapeutics
Wendy Naimark, PhD, is Chief Technology Officer at Ripple Therapeutics, with over 20 years of experience advancing novel therapeutics across biotech, pharma, and combination device sectors. She has led programs from first-in-human trials to regulatory approval in both startups and large corporations. Her expertise spans clinical and preclinical development, regulatory strategy, and complex drug-device integration. Wendy has held leadership roles at Boston Scientific, 480 Biomedical, and Interface Biologics, and earned her PhD from Caltech, where she also completed a postdoctoral fellowship in protein polymer engineering.
Seminars
This panel will discuss collaboration in delivery development i.e., co-developing platforms, managing device timelines, and regulatory alignment in combo products.
- Strategies to leverage the speed and innovation of biotech startups alongside the deep experience and resources of pharma giants like AbbVie: turning potential clashes into powerful synergies
- What “we’re thoroughly enjoying our AbbVie relationship” means in practice: how both Ripple Therapeutics and AbbVie have fostered continuous learning and development through close cooperation during diligence, development planning, and execution phases
- The importance of proactive, transparent communication, and collaboration across functions, including early alignment with device teams and other stakeholders, to anticipate challenges and optimize program success
